Show simple item record

dc.contributor.authorBora, Gamze
dc.contributor.authorSari, Suat
dc.contributor.authorTaskor, Gulce
dc.contributor.authorDalkara, Sevim
dc.contributor.authorErdem-Yurter, Hayat
dc.date.accessioned2021-06-03T06:03:30Z
dc.date.available2021-06-03T06:03:30Z
dc.date.issued2019
dc.identifier.issn2630-6344
dc.identifier.urihttp://dx.doi.org/10.35333/jrp.2019.42
dc.identifier.urihttp://hdl.handle.net/11655/24184
dc.description.abstractHistone deacetylases (HDAC) are evolutionary conserved enzymes, which catalyze removal of acetyl groups from histone and non-histone proteins, therefore, control multiple biological processes. Inhibition of their activities have been investigated to modify gene expression and/or protein functions not only for treatment of certain diseases but also for understanding functions of deacetylase isoforms. We previously synthesized aryl butenoic acid derivatives and identified their pan-HDAC inhibition activities. In this study, we investigated selective inhibition activities of these derivatives (C1, C3, C4) on class I HDACs using in silico and in vitro approaches. Molecular docking studies of the three aryl butenoic acid derivatives were performed on the crystal structures of HDAC 1, 2, 3 and 8, which were obtained from RCSB protein databank, using Glide software. In vitro inhibition activities of the compounds at two different concentrations were tested using fluorometric assay. In silico results indicated that all the compounds showed higher affinity to HDAC 1 and 8 than other class I deacetylases. In vitro analysis showed that the compounds inhibit HDAC 8 more effectively than HDAC 1. It was shown that C1 had higher binding affinity and inhibition activity to both enzymes. We concluded that, C1 inhibited both HDAC 1 and 8, however, C3 and C4 showed slight selectivity for HDAC 8 over HDAC 1, which was in agreement with the docking studies. Further cell culture studies will be valuable to determine increased acetylation on target proteins in response to compound treatment.
dc.language.isoen
dc.relation.isversionof10.35333/jrp.2019.42
dc.rightsAttribution 4.0 United States
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectaryl butenoic acid derivatives
dc.subjectHistone deacetylase inhibitors
dc.subjectin vitro activity screening
dc.subjectmolecular docking
dc.titleClass I Histone Deacetylase Inhibition By Aryl Butenoic Acid Derivatives: In Silico And In Vitro Studies
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalJournal Of Research In Pharmacy
dc.contributor.departmentTıbbi Biyoloji
dc.identifier.volume23
dc.identifier.issue5
dc.description.indexWoS
dc.description.indexScopus


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 United States
Except where otherwise noted, this item's license is described as Attribution 4.0 United States